Geneva/Berlin/Ingelheim/Bonn, 20th February 2014. Amal Therapeutics SA, a Swiss and German-based company focusing on the development of therapeutic cancer vaccines, announced today that it has closed its seed financing round. The funds will be used to consolidate the cell-penetrating peptide based technology platform and progress the first vaccine candidate up to pre-clinical development. The investment […]
This author has yet to write their bio.Meanwhile lets just say that we are proud canvax contributed a whooping 23 entries.
Entries by canvax
Amal Therapeutics received the support from the “Eidgenössische Stiftung zur Förderung Schweizerische Volkswirtschaft durch wissenschaftlische Forschung”.
Amal Therapeutics received a CTI grant for a research project in collaboration with the Laboratory of Tumor Immunology, University of Geneva.